4/12/2013

A Series A funding round led by Arch Venture Partners and Flagship Ventures has brought in $30 million to Syros Pharmaceuticals, which is developing treatment techniques based on advanced genetic sequencing and insights into how proteins control genetic expression in stem cells. The Watertown, Mass.-based biotech startup will use the money to expedite the discovery and development of proteins it calls super enhancers.

Related Summaries